Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts

by Christoph Goletz, Timo Lischke, Ulf Harnack, Phillip Schiele, Antje Danielczyk, Johanna Rühmann, Steffen Goletz
Published 2018-07-01